OTC:ACOGF Alpha Cognition (ACOGF) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free ACOGF Stock Alerts C$0.50 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share Today's RangeC$0.49▼C$0.5050-Day RangeC$0.49▼C$0.6752-Week RangeC$0.14▼C$0.74Volume1,725 shsAverage Volume33,155 shsMarket CapitalizationC$53.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get Alpha Cognition alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Alpha Cognition Stock (OTC:ACOGF)Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.Read More ACOGF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACOGF Stock News HeadlinesApril 3, 2024 | businesswire.comAlpha Cognition Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate UpdateApril 2, 2024 | finance.yahoo.comPresenting on the Emerging Growth Conference 69 Day 1 on April 3 Register NowApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 20, 2024 | businesswire.comAlpha Cognition to Present at the Emerging Growth Conference on April 3, 2024 at 12:00pm EDT.March 5, 2024 | finance.yahoo.comLife Science Virtual Investor Forum Agenda Announced for March 7th, 2024March 1, 2024 | finance.yahoo.comAlpha Cognition to Present at the Life Science Investor Forum March 7thFebruary 22, 2024 | businesswire.comAlpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer's DiseaseFebruary 12, 2024 | finance.yahoo.comAlpha Cognition Provides Business UpdateApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.February 6, 2024 | finance.yahoo.comACOGF: Obtaining CapitalFebruary 6, 2024 | finance.yahoo.comACOGF: Full Year 2022 Financial ReportDecember 29, 2023 | nasdaq.comAlpha Cognition Inc (ACOGF)December 22, 2023 | finance.yahoo.comAlpha Cognition Announces Fourth Closing of Private Placement and Continuation of the OfferingDecember 8, 2023 | msn.comFDA accepts Alpha Cognition’s NDA for Alzheimer’s diseaseDecember 7, 2023 | stockhouse.comAlpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer's DiseaseDecember 7, 2023 | finance.yahoo.comAlpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s DiseaseDecember 4, 2023 | finance.yahoo.comAlpha Cognition Announces Amended Terms of Private Placement and Continuation of the OfferingNovember 14, 2023 | morningstar.comAlpha Cognition Inc Ordinary Shares ACOGFNovember 8, 2023 | finance.yahoo.comAlpha Cognition Announces Third Closing of Private Placement and Continuation of the OfferingOctober 2, 2023 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - ACOG.WTSeptember 27, 2023 | finance.yahoo.comAlpha Cognition Announces Submission of New Drug Application to the FDA for ALPHA-1062 for Mild-to-Moderate Alzheimer’s DiseaseSeptember 20, 2023 | forbes.comWolfram Alpha, Meet ChatGPT: Stephen Wolfram Talks Intelligence And Large Language ModelsAugust 31, 2023 | finance.yahoo.comAlpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the OfferingAugust 22, 2023 | msn.comAlpha Cognition GAAP EPS of -$0.03August 22, 2023 | finance.yahoo.comAlpha Cognition Announces Second Quarter and Six Months Ended 2023 Results and Provides Corporate UpdateAugust 14, 2023 | finance.yahoo.comAlpha Cognition Receives Notice of Allowance for U.S. Patent Application covering use of ALPHA-1062 for Mild to Moderate Alzheimer’s DiseaseAugust 11, 2023 | finance.yahoo.comACOGF - Alpha Cognition Inc.See More Headlines Receive ACOGF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alpha Cognition and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTC SectorMedical Industry N/A Sub-IndustryN/A Current SymbolOTC:ACOGF CUSIPN/A CIKN/A Webwww.alphacognition.com Phone604-564-9244FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-13,770,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-382.20% Debt Debt-to-Equity RatioN/A Current Ratio0.73 Quick Ratio0.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueC($0.04) per share Price / Book-12.32Miscellaneous Outstanding Shares108,900,000Free Float74,576,000Market CapC$53.67 million OptionableNot Optionable Beta2.86 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Michael E. McFadden (Age 57)CEO & Director Comp: $655.19kMr. Kenneth Anthony Cawkell B.A. (Age 73)LL.B., Founder, Special Advisor, Corporate Secretary & Director Comp: $97.23kMr. Donald A. Kalkofen B.A. (Age 60)Chief Financial Officer Comp: $546.1kMs. Lauren D'Angelo M.B.A.Chief Operating OfficerDr. Denis G. Kay Ph.D. (Age 67)Chief Scientific Officer Comp: $180kMs. Colleen JohnsSenior Vice President of Product DevelopmentMore ExecutivesKey CompetitorsAutonomix MedicalNASDAQ:AMIXEnzo BiochemNYSE:ENZReneo PharmaceuticalsNASDAQ:RPHMIceCure MedicalNASDAQ:ICCMSensus HealthcareNASDAQ:SRTSView All Competitors ACOGF Stock Analysis - Frequently Asked Questions How have ACOGF shares performed in 2024? Alpha Cognition's stock was trading at C$0.50 at the start of the year. Since then, ACOGF stock has decreased by 0.8% and is now trading at C$0.49. View the best growth stocks for 2024 here. How do I buy shares of Alpha Cognition? Shares of ACOGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTC:ACOGF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpha Cognition Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
